Sofgen Pharma S.A.
Other OTCTotal Valuation
Sofgen Pharma S.A. carries a market capitalization of 219,475.00, placing it among publicly traded companies globally. Its enterprise value stands at 274.73M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 219,475.00 |
| Enterprise Value | 274.73M |
Share Statistics
Sofgen Pharma S.A. currently has 101.11M shares outstanding.
| Shares Outstanding | 101.11M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
On an enterprise value basis, Sofgen Pharma S.A. trades at an EV/EBITDA multiple of 4.40 and an EV/FCF ratio of 1.56. The EV/Sales ratio of 0.65 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 6.21 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.65 |
| EV / EBITDA | 4.40 |
| EV / EBIT | 6.21 |
| EV / FCF | 1.56 |
Financial Position
Sofgen Pharma S.A. maintains a current ratio of 0.64, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -40,693.34, indicating conservative leverage, while an interest coverage ratio of 1.53 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.64 |
| Quick Ratio | 0.39 |
| Debt / Equity | -40,693.34 |
| Debt / EBITDA | 4.79 |
| Interest Coverage | 1.53 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 8.82 |
| Return on Invested Capital (ROIC) | 14.44 |
| Return on Capital Employed (ROCE) | -62.95 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.84 |
Taxes
Over the trailing twelve months, Sofgen Pharma S.A. has paid 5.62M in income taxes, reflecting an effective tax rate of 12.22.
| Income Tax | 5.62M |
| Effective Tax Rate | 12.22 |
Income Statement
EBITDA reached 62.47M, while operating income came in at 44.28M.
| Revenue | 423.75M |
| Gross Profit | 237.98M |
| Operating Income | 44.28M |
| Pretax Income | 45.96M |
| Net Income | 40.34M |
| EBITDA | 62.47M |
| EBIT | 44.28M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Sofgen Pharma S.A. holds 23.82M in cash and equivalents against 299.50M in total debt, resulting in a net debt position of 281.99M. Total book value stands at -395.27M, with working capital of -157.92M providing operational flexibility.
| Cash & Cash Equivalents | 23.82M |
| Total Debt | 299.50M |
| Net Debt | 281.99M |
| Equity (Book Value) | -395.27M |
| Book Value Per Share | N/A |
| Working Capital | -157.92M |
Cash Flow
Sofgen Pharma S.A. produced 107.64M in operating cash flow over the past twelve months.
| Operating Cash Flow | 107.64M |
| Capital Expenditures | -32.79M |
| Free Cash Flow | 74.84M |
| FCF Per Share | N/A |
Margins
Sofgen Pharma S.A. operates with a gross margin of 56.16, reflecting its pricing power and cost economics. The operating margin of 10.45 and net profit margin of 9.52 provide insight into operational efficiency.
| Gross Margin | 56.16 |
| Operating Margin | 10.45 |
| Pretax Margin | 10.85 |
| Profit Margin | 9.52 |
| EBITDA Margin | 14.74 |
Scores
Sofgen Pharma S.A. posts an Altman Z-Score of -0.41, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.41 |